News of Note—Flu vaccines, CureVac and more

newspaper
In this week's news of note, InvVax reported positive preclinical results for a universal flu vaccine candidate. (Pixabay)

Here is some other vaccine news of note for the week:

> About 37% of U.S. adults got a flu vaccine last year, according to the CDC. The figure represented about a 6% decline from the prior year. MarketWatch article

> CureVac started a phase 1 study of a mRNA-based rabies vaccine candidate. Release

> ImmusanT kicked off a phase 2 study of its Nexvax2 in patients with celiac disease. Release

> A report found that low vaccine confidence in Europe is contributing to a higher number of disease outbreaks. Reuters article

> Privately held biotech InvVax touted preclinical results for its universal flu vaccine candidate. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.